Information Library

Results for: Endocrinology - High-quality studies

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Intarcia and Quintiles Finalize Innovative Alliance

    Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).

  • Clinical Endpoint Committees - Summary

    White Paper — March 6, 2011
    What are regulatory boards looking for in clinical endpoint committees? Read our executive summary on the current best practice across the industry.

  • Clinical Endpoint Committees

    White Paper — February 22, 2011
    As regulatory boards are expecting more from clinical endpoint committees, what guidance can you follow? This white paper sets forth current best practice for CECs.

  • Clinical – Smarter Trials, Accelerated Outcomes

    Brochure — February 16, 2011
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • Data-Driven Market Success

    Case Study — May 14, 2010
    Steering the largest post-marketing diabetes study ever conducted, Quintiles was able to stay flexible and successfully scale up to an eight-country study with more than 55,000 patients, even with the operational challenges of multiple affiliates and staggered database locks.

  • Regulatory Landscapes for Future Antidiabetic Drug Development

    Hear from the Experts — May 12, 2010
    In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • Early Phase Optimization Strategies

    Media Coverage — November 18, 2009
    As payers balk at rising drug prices and patent expirations threaten the industry’s revenue streams, pharmaceutical companies worldwide are looking for ways to cut costs associated with drug development and, simultaneously, speed the process up.

  • Precision Planning

    Case Study — September 17, 2009
    Proactive planning yields high-quality data. Eight countries. More than 55,000 patients. Robust data management kept this post-marketing diabetes study on track and on time

  • Diabetes Report

    Brochure — September 9, 2009
    Example for possible customer report for specifc therapy area. Example used: diabetes

Page 1 of 2 (11 results)

Subscribe to Email Based on Your Interests

Set preferences